News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vaxart, Inc.’s Oral H1N1 Influenza Vaccine Generates Protective Immunity



1/9/2014 10:20:57 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN FRANCISCO--(BUSINESS WIRE)--Vaxart, a privately held company developing recombinant vaccines that are administered by tablet rather than by injection, today announced positive safety and immunogenicity data from a phase Ib clinical dose-ranging study with its oral H1N1 seasonal influenza vaccine candidate. This study follows a phase I study, the positive results of which were announced in June 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   
Influenza

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES